No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 979 | 1,220 | 1,486 | 1,583 | 1,606 | 1,178 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 45 | 207 | 291 | 493 | 350 | 190 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Boai NKY Medical Holdings Ltd. is an international enterprise specializing in the development, production, and global distribution of polyvinylpyrrolidone (PVP) series products. Its extensive product portfolio features pharmaceutical excipients such as Povidone, Crospovidone, and Copovidone, marketed under the KoVidone and PolyKoVidone brand lines. The company also manufactures OraRez PVM/MA copolymers and their derivatives, which are specialized functional polymers vital for bioadhesive and mucoadhesive applications. Additionally, it supplies KoVidone-1, a broad-spectrum agent with biocidal, antifungal, and antiviral efficacy. Further offerings encompass a wide array of chemical solutions, including pharmaceutical solvents, intermediates, various polymers, and vinyl and vinyl ether compounds. Specific branded products like PolyViscol, KoVidone I, WhiVidone, and PVPP are also part of their catalog. These diverse chemical components find integral application across numerous industries, including pharmaceuticals, industrial processes, oral care products, cosmetics, and the food and beverage sector. Founded in Heping, China, in 1987, the company was initially known as Boai NKY Pharmaceuticals Ltd. It transitioned to its current designation, Boai NKY Medical Holdings Ltd., in March 2016.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Boai NKY Medical Holdings Ltd. (300109.SZ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Boai NKY Medical Holdings Ltd. is an international enterprise specializing in the development, production, and global distribution of polyvinylpyrrolidone (PVP) series products. Its extensive product portfolio features pharmaceutical excipients such as Povidone, Crospovidone, and Copovidone, marketed under the KoVidone and PolyKoVidone brand lines. The company also manufactures OraRez PVM/MA copolymers and their derivatives, which are specialized functional polymers vital for bioadhesive and mucoadhesive applications. Additionally, it supplies KoVidone-1, a broad-spectrum agent with biocidal, antifungal, and antiviral efficacy. Further offerings encompass a wide array of chemical solutions, including pharmaceutical solvents, intermediates, various polymers, and vinyl and vinyl ether compounds. Specific branded products like PolyViscol, KoVidone I, WhiVidone, and PVPP are also part of their catalog. These diverse chemical components find integral application across numerous industries, including pharmaceuticals, industrial processes, oral care products, cosmetics, and the food and beverage sector. Founded in Heping, China, in 1987, the company was initially known as Boai NKY Pharmaceuticals Ltd. It transitioned to its current designation, Boai NKY Medical Holdings Ltd., in March 2016.